2023
DOI: 10.1016/j.ejmech.2023.115422
|View full text |Cite
|
Sign up to set email alerts
|

Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 109 publications
0
6
0
Order By: Relevance
“…Approximately 90% of MBC expresses ER, and 81% expresses progesterone receptor (PR). 100 102 Comparatively papillary carcinoma is one of the most prevalent types and lobular carcinomas are rare. 103 However, a recent study by Chhabra et al, in the year 2021, showed around 81% of ER, 76% PR, 25% HER2neu , and 2% of TNBC in Indian population.…”
Section: Ductal Carcinoma In Situ (Dcis)mentioning
confidence: 99%
“…Approximately 90% of MBC expresses ER, and 81% expresses progesterone receptor (PR). 100 102 Comparatively papillary carcinoma is one of the most prevalent types and lobular carcinomas are rare. 103 However, a recent study by Chhabra et al, in the year 2021, showed around 81% of ER, 76% PR, 25% HER2neu , and 2% of TNBC in Indian population.…”
Section: Ductal Carcinoma In Situ (Dcis)mentioning
confidence: 99%
“…In human mammary glands, the majority of the GH-IGF1 axis’ effects is mediated by serum and locally produced IGF1. However, in breast cancer, GH has been shown to enhance proliferation, survival, invasion and angiogenesis in cancer cells, independent of IGF1 [ 114 , 115 ]. The IGF signaling involves a complex system composed of three ligands (IGF1, IGF2 and insulin), many membrane receptors and six high-affinity binding proteins (IGFBP1 to IGFBP6) [ 116 ].…”
Section: Gh-igf1 Axis and Tumor Development: The Role Of Estrogensmentioning
confidence: 99%
“…Main SERMs, SERDs, AI and estrogens with related molecular and pharmacological features. The references used in this table are[92,[114][115][116][117].…”
mentioning
confidence: 99%
“…Some small-molecule examples of SERDs have been disclosed in the literature (e.g., WO2005073204, WO2014205136, and WO2016097071). There has been a recent shift of focus in research on endocrine therapies toward SERDs as the development of resistance against SERMs grows ( Bhatia et al, 2023 ). These SERDs can be used either as single agents or in combination with other classes of drugs, including SERMs, aromatase inhibitors, CDK4/CDK6 inhibitors, PI3K inhibitors, and mTOR inhibitors to treat hormone receptor-positive BC.…”
Section: Introductionmentioning
confidence: 99%